

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-29 (canceled)

Claim 30 (new): A method for identifying genomic regions displaying transcription from both DNA strands comprising:

- obtaining a sample comprising transcripts transcribed from the genomic regions;
- synthesizing single stranded cDNAs complementary to the transcripts wherein synthesis of the second strand cDNA is inhibited;
- hybridizing the cDNAs or nucleic acids derived from the cDNAs with a nucleic acid probe array, wherein the nucleic acid probe array comprises probes targeting both strands of the genomic regions;
- measuring hybridization intensities; and
- identifying genomic regions that display positive hybridization intensities for both strands of the genomic regions.

Claim 31 (new): The method of claim 30 wherein the synthesis of the second strand cDNAs is inhibited by the presence of actinomycin.

Claim 32 (new): The method of claim 31 wherein the cDNAs or nucleic acids derived from cDNAs are labeled.

Claim 33 (new): The method of claim 32 wherein the nucleic acid probe array is an oligonucleotide probe array.

Claim 34 (new): The method of claim 33 wherein the nucleic acid probe array has at least 400 probes per  $\text{cm}^2$ .

Claim 35 (new): The method of claim 34 wherein the nucleic acid probe array has at least 1000 probes per  $\text{cm}^2$ .

Claim 36 (new): The method of claim 35 wherein the nucleic acid probe array has at least 10000 probes per  $\text{cm}^2$ .

Claim 37 (new): A method for identifying antisense drug targets comprising:

- obtaining a sample comprising transcripts transcribed from genomic regions of interest;
- synthesizing single stranded cDNAs complementary to the transcripts wherein synthesis of the second strand cDNA is inhibited;
- hybridizing the cDNAs or nucleic acids derived from the cDNAs with a nucleic acid probe array, wherein the nucleic acid probe array comprises probes targeting both strands of the genomic regions;
- measuring the relative expressions of sense and antisense transcripts transcribed from the same genomic region; and
- selecting the region with substantially more antisense transcription as a potential antisense drug target.

Claim 38 (new): The method of claim 37 wherein the synthesis of the second strand cDNAs is inhibited by the presence of actinomycin.

Claim 39 (new): The method of claim 38 wherein the cDNAs or nucleic acids derived from cDNAs are labeled.

Claim 40 (new): The method of claim 39 wherein the nucleic acid probe array is an oligonucleotide probe array.

Claim 41 (new): The method of claim 40 wherein the nucleic acid probe array has at least 400 probes per  $\text{cm}^2$ .

Claim 42 (new): The method of claim 41 wherein the nucleic acid probe array has at least 1000 probes per  $\text{cm}^2$ .

Claim 43 (new): The method of claim 42 wherein the nucleic acid probe array has at least 10000 probes per  $\text{cm}^2$ .